ArticleTherapeutic advances in musculoskeletal disease2026
The association between glucagon-like peptide-1 receptor agonists and reported musculoskeletal adverse events: a systematic review and meta-analysis of randomized controlled trials.
Article in Therapeutic advances in musculoskeletal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a major risk factor for musculoskeletal disorders. Glucagon-like peptide-1 receptor (GLP-1R)-based agonists facilitate weight loss and may influence musculoskeletal health. However, whether GLP-1R based agonists are associated with the musculoskeletal adverse events during the treatment remains unclear. Objectives: To assess the association between the use of GLP-1R agonists (GLP-1RA) and the spontaneous reports of musculoskeletal adverse events based on RCT safety data. Design: A systematic review and meta-analysis of RCTs. Methods: Results: A total of 43 RCTs with 100,488 participants were included. No significant difference was observed between users of GLP-1RAs and the control group in the reporting of the prespecified musculoskeletal adverse events, including gouty arthritis, rheumatoid arthritis, osteoarthritis, osteoporotic fracture, synovitis, or intervertebral disc protrusion. However, a higher proportion of male participants was associated with fewer reports of osteoarthritis (β = -0.015, 95% CI, -0.029 to -0.001) in GLP-1R-based agonist users. Conclusion: GLP-1RAs were not associated with the spontaneously reported events of gouty arthritis, rheumatoid arthritis, osteoarthritis, osteoporotic fracture, synovitis, or intervertebral disc protrusion. A higher percentage of male participants was associated with fewer reports of osteoarthritis among GLP-1RA users.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.